|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500101313 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-23 11:43:36 |
|
注册时间: Date of Registration: |
2025-04-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
CCLG-CML2025酪氨酸激酶抑制剂减/停方案多中心临床研究 |
|
Public title: |
Multicenter clinical study of CCLG-CML2025 protocol for Tyrosine kinase inhibitor de-escalation/intermittence and cessation |
|
注册题目简写: |
Multicenter clinical study of CCLG-CML2025 protocol |
|
English Acronym: |
Multicenter clinical study of CCLG-CML2025 protocol |
|
研究课题的正式科学名称: |
CCLG-CML2025酪氨酸激酶抑制剂减/停方案多中心临床研究 |
|
Scientific title: |
Multicenter clinical study of CCLG-CML2025 protocol for Tyrosine kinase inhibitor de-escalation/intermittence and cessation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
董丁丁 |
研究负责人: |
郑胡镛 |
|
Applicant: |
Dong Dingding |
Study leader: |
Huyong Zheng |
|
申请注册联系人电话: Applicant telephone: |
+86 18813038056 |
研究负责人电话: Study leader's telephone: |
+86 10 59617600 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dongdingding666@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhenghuyong@bch.com.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国北京市西城区南礼士路56号 |
研究负责人通讯地址: |
北京市西城区南礼士路56号 |
|
Applicant address: |
No.56 Nan Lishi Road, Xicheng District, Beijing P.R China |
Study leader's address: |
Nanlishi Road 56#,Xicheng District,Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
首都医科大学附属北京儿童医院 |
||
|
Applicant's institution: |
Beijing Children's Hospital, Capital Medical University |
||
|
研究负责人所在单位: |
首都医科大学附属北京儿童医院 |
||
|
Affiliation of the Leader: |
Beijing Childrens Hospital,Capital Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025]-Y-065-D |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
首都医科大学附属北京儿童医院医学伦理委员会(A组) |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Beijing Children's Hospital, Capital Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-01 00:00:00 |
||
|
伦理委员会联系人: |
张怡 |
||
|
Contact Name of the ethic committee: |
Zhang Yi |
||
|
伦理委员会联系地址: |
北京市西城区南礼士路56号 |
||
|
Contact Address of the ethic committee: |
Nanlishi Road 56#,Xicheng District,Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 59616083 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zyhoney819@163.com |
|
研究实施负责(组长)单位: |
首都医科大学附属北京儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Childrens Hospital,Capital Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市西城区南礼士路56号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Nanlishi Road 56#,Xicheng District,Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised |
||||||||||||||||||||||
|
Target disease: |
Chronic Myeloid Leukemia |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.本课题将对达到深度分子学缓解的CML患儿实施TKI的“减量-停药”或“间断停药”的策略,探究“减量-停药”或“间断停药”策略是否能减少药物对生长发育的影响,提高生活质量。 2.本课题将探究影响深度分子学缓解CML患儿减量或间断停药过程中丧失MMR的影响因素,探索适宜的减量或间断停药策略。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. The study is going to evaluate if the "de-escalation-cessation" and "intermittence-cessation" strategies could reduce the adverse effect of tyrosine kinase inhibitors on growth and development of children and adolescent with chronic myeloid leukemia who have achieved sustained deep molecular remission. 2. The study is going to explore the factors influencing the maintenance or loss of major molecular remission, and develop approriate strategies for de-escalation, intermittence, and cessation of TKI in children and adolescents with CML. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.明确诊断为CML-CP,年龄小于18岁; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients who are 18 years or younger, and have a diagnosis of CML chronic phase; 2. Patients who have been taking TKI for ≥ 36 months and have not experienced treatment failure (according to the definitions in ELN recommendations); 3. Patients must have a history of stable molecular response, defined as MR4 for ≥24 months, as documented by ≥5 separate tests; 4. Patients and/or their guardian are willing to give their consent to participate to the study. |
||||||||||||||||||||||
|
排除标准: |
1.曾出现CML加速期或急变期; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. A history of blast crisis or accelerated phase; 2. Previous tyrosine kinase inhibitor resistance; 3. Patient has received hematopoietic stem cell transplantation or immunotherapy (including interferon); 4. There are two or more significant abnormalities in the blood routine; 5. Another malignant disease; 6. Patients complicated with any other diseases or psychiatric disease that could affect their safety and compliance, informed consent, participation, follow-up or interpretation of results. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-30 00:00:00至 To 2030-04-29 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-04-30 00:00:00 至 To 2030-04-29 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究负责人可通过邮件共享数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Research leaders can share data via email |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过电子表格进行数据采集,由专人进行数据管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection through spreadsheets and data management by a dedicated person |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |